ArticleFrontiers in bioengineering and biotechnology2025
A dynamically tunable terahertz human serum albumin biosensor based on Dirac semimetal nanozyme.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents a tunable terahertz biosensor based on a hybrid architecture integrating bulk Dirac semimetal (BDS) with a photonic crystal for the label-free and highly sensitive detection of human serum albumin (HSA). The sensor exhibits a sharp Fano resonance resulting from the synergistic coupling between a defect mode and the BDS-mediated plasmonic response, with its resonance frequency being highly sensitive to variations in the refractive index of the sensing layer. Electric field simulations confirm significant field confinement and enhancement within the sensing region. The electrically tunable property of BDS allows dynamic reconfiguration of the sensor's sensitivity by adjusting the Fermi level (0.1-0.4 eV), though at the expense of a reduced figure of merit (FOM) due to broader resonance peaks and increased loss, necessitating a balance in practical implementations. Structural parameter analysis reveals that sensitivity is inversely proportional to the sensing layer thickness and gradually decreases with increasing refractive index. The proposed biosensor achieves a reflection dip deeper than 99% near 1 THz, with an angular sensitivity of 247.5°/RIU for minute refractive index changes (Δn = 0.002), demonstrating high sensitivity and excellent electrical tunability. This platform demonstrates pioneering potential in integrating diagnostic-treatment nanotechnology. Due to the powerful local field enhancement generated by the BDS photonic crystal heterostructure, the imaging sensitivity of the contrast agent based on nanoenzymes has been significantly improved. Moreover, the profound local field enhancement and dynamic tunability of this platform suggest its potential for real-time monitoring and regulation of the catalytic efficiency of nanoenzymes, which could address a fundamental challenge in therapeutic applications. Combined with its inherent biocompatibility and strong detection capabilities, this framework proposes a viable pathway toward the clinical translation of nanoenzyme technology. Our work thus establishes a foundational platform that paves the way for future multifunctional theranostic systems capable of combining sensitive biomarker monitoring with enhanced therapeutic effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.